Type 2 Diabetes Prevalence Rose in the United States From 2012 to 2022
By Lori Solomon HealthDay Reporter
FRIDAY, Aug. 23, 2024 -- The prevalence of diabetes increased in the United States from 2012 to 2022, according to a research letter published online July 18 in Diabetes, Obesity and Metabolism.
Sulakshan Neupane, from the University of Georgia in Athens, and colleagues examined recent national trends and disparities in self-reported diabetes prevalence among U.S. adults. The analysis included 5.3 million participants in the Behavioral Risk Factor Surveillance System (2012 to 2022).
The researchers found that the overall prevalence of diabetes increased significantly by 18.6 percent during the study period, across all sociodemographic groups. The prevalence was highest among non-Hispanic Black people (15.8 percent) and individuals aged 65 years and older (23.86 percent). Compared with non-Hispanic White individuals, odds were higher among Hispanic individuals (adjusted odds ratio [aOR], 1.60), non-Hispanic Asians (aOR, 1.67), and non-Hispanic Black individuals (aOR, 2.10). Men had a slightly higher prevalence than women (12.56 versus 11.56 percent). Prevalence was 56 percent higher among individuals with lower incomes. Individuals with obesity faced the highest prevalence -- 19.23 percent -- compared with individuals with normal weight.
"This study showed significant increases in diabetes prevalence across the United States from 2012 to 2022, aligning with previous research demonstrating rising trends nationally over recent decades," the authors write. "Persistently high and increasing prevalence underscores the alarming diabetes epidemic facing the United States."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
GLP-1 Receptor Agonists Not Linked to Increased Risk of Psychiatric Adverse Events, Depression
MONDAY, May 19, 2025 -- For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased...
Preoperative SGLT2 Inhibitor Users Have Increased Risk for Postoperative Euglycemic Ketoacidosis
TUESDAY, May 13, 2025 -- Patients using sodium-glucose cotransporter 2 inhibitors (SGLT2i) preoperatively have a slightly increased risk for postoperative euglycemic ketoacidosis...
GLP-1 Receptor Agonists Reduce Alcohol Intake in Patients Treated for Obesity
MONDAY, May 12, 2025 -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are tied to a reduction in alcohol intake, according to a research letter recently published in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.